Cure8 research brief
Why This Matters
Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.
Who Should Pay Attention
Researchers in IBD epidemiology, public-health analysts, clinicians and policymakers using GBD estimates
Study Snapshot
What To Know
The paper matched GBD 2023 rates to population-based incidence and prevalence observations from GIVES-21 and assessed agreement using Bland–Altman differences, Deming regression, and concordance correlation coefficients.
Median GBD-to-GIVES ratios were generally below 1 (GBD lower than observed) across incidence and prevalence for both UC and CD, and concordance varied by outcome and sensitivity analyses.
The authors emphasize that both data sources are imperfect: the analysis quantifies agreement but does not establish which source reflects the true underlying rates nor support applying a single correction factor to GBD estimates.
Keep In Mind
Structured content depth is abstract from a posted research paper on Research Square; it summarizes the authors' analyses but has not undergone peer review.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.